biostudies-literatureDoan NQHUniversity of Medicine and Pharmacy at Ho Chi Minh City33963-33984https://www.ebi.ac.uk/biostudies/studies/S-EPMC9520563biostudies-literatureUnknown7(38)Addressing the growing burden of cancer and the shortcomings of chemotherapy in cancer treatment are the current research goals. Research to overcome the limitations of curcumin and to improve its anticancer activity via its heterocycle-fused monocarbonyl analogues (MACs) has immense potential. In this study, 32 asymmetric MACs fused with 1-aryl-1<i>H</i>-pyrazole (<b>7a-10h</b>) were synthesized and characterized to develop new curcumin analogues. Subsequently, via initial screening for cytotoxic activity, nine compounds exhibited potential growth inhibition against MDA-MB-231 (IC₅₀ 2.43-7.84 μM) and HepG2 (IC₅₀ 4.98-14.65 μM), in which seven compounds showing higher selectivities on two cancer cell lines than the noncancerous LLC-PK1 were selected for cell-free <i>iACS omegaSynthesis, Biological Evaluation, and Molecular Modeling Studies of 1-Aryl-1<i>H</i>-pyrazole-Fused Curcumin Analogues as Anticancer Agents.PMC952056302/2020/H-HYDNguyen NTKDuong DNTruong TNDuong VBNguyen HTTDo TTHNguyen NTDoan NQHVong LBNguyen TLTfalseSynthesis, Biological Evaluation, and Molecular Modeling Studies of 1-Aryl-1<i>H</i>-pyrazole-Fused Curcumin Analogues as Anticancer Agents.Addressing the growing burden of cancer and the shortcomings of chemotherapy in cancer treatment are the current research goals. Research to overcome the limitations of curcumin and to improve its anticancer activity via its heterocycle-fused monocarbonyl analogues (MACs) has immense potential. In this study, 32 asymmetric MACs fused with 1-aryl-1<i>H</i>-pyrazole (<b>7a-10h</b>) were synthesized and characterized to develop new curcumin analogues. Subsequently, via initial screening for cytotoxic activity, nine compounds exhibited potential growth inhibition against MDA-MB-231 (IC₅₀ 2.43-7.84 μM) and HepG2 (IC₅₀ 4.98-14.65 μM), in which seven compounds showing higher selectivities on two cancer cell lines than the noncancerous LLC-PK1 were selected for cell-free <i>i2022-01-01T00:00:00Z2022 Sep2026-05-27T19:11:42.24Z2025-05-18T12:50:00.713ZS-EPMC95205633618833110.1021/acsomega.2c02933